ArticleInternational journal of nanomedicine2026
Simvastatin and Moxifloxacin Co-Delivery via ZIF-8/PDA Coating on PEEK Implants: A Strategy for Combating Implant-Associated Infection and Enhancing Osseointegration.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polyetheretherketone (PEEK) is a promising orthopedic implant material due to its bone-matched elastic modulus and radiolucency. However, its clinical application is limited by biological inertness and lack of antibacterial activity, which predispose to implant-associated infection (IAI) and poor osseointegration. This study developed a multifunctional coating on sulfonated PEEK (SPEEK) via polydopamine (PDA)-mediated co-delivery of simvastatin-loaded ZIF-8 nanoparticles (SIM@ZIF-8) and moxifloxacin (MOX) to address these limitations. Methods: A time-programmed release coating was fabricated on SPEEK by embedding SIM@ZIF-8 within a PDA layer and surface-loading MOX onto the surface. The coating's physicochemical properties, drug release profiles, biocompatibility, antibacterial activity, and osteogenic capacity were evaluated in vitro. Antibacterial efficacy and osseointegration were further assessed in vivo using rat subcutaneous infection and rabbit femoral defect models. Results: Release profiles revealed that MOX exhibited burst release within 24 h, whereas SIM quickly reached therapeutic concentrations during the initial phase and was slowly released over five weeks, while Zn Conclusion: This study presents a novel bioactive PEEK implant coating integrating antibacterial and osteogenic functions through a MOX/SIM@ZIF-8/PDA system. The strategy effectively combats IAI and enhances osseointegration, offering potential for clinical orthopedic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.